Instrument Inactif

Communiqués Orchard Therapeutics plc Börse Stuttgart

Actions

OT10

US68570P2002

Produits pharmaceutiques

Communiqués

07/05/24	Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024	AQ
06/05/24	Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List	AQ
03/05/24	Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List	AQ
03/04/24	FDA Approves First Gene Therapy To Treat Children With Metachromatic Leukodystrophy	AQ
20/03/24	FDA approves innovative gene therapy for MLD	AQ
20/03/24	Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy	AQ
18/03/24	Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.	AQ
05/02/24	Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome	AQ
02/02/24	Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium	AQ
26/01/24	Kyowa Kirin Co., Ltd - Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc	AQ
25/01/24	Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy	AQ
24/01/24	Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases	AQ
11/12/23	Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD	AQ
30/11/23	Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH	AQ
28/11/23	ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX	BU
13/11/23	Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments	AQ
26/10/23	Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023	AQ
24/10/23	Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023	AQ
06/10/23	ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX	BU
05/10/23	Kyowa Kirin to Acquire Orchard Therapeutics	AQ
18/09/23	Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review	AQ
31/08/23	Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023	AQ
03/08/23	Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA	AQ
02/08/23	Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel	AQ
01/08/23	Orchard Therapeutics : Corporate Presentation - August 2023	PU